Passamonti et al reported an International Prognostic Score for patients with essential thrombocythemia. This can help to identify a patient at risk for thrombosis and worse survival who may benefit from more aggressive management. The authors are from multiple universities in Europe participating in the International Working Group on Myelofibrosis Research and Treatment.
NOTE The IPSET of Barbui et al is discussed in Chapter 04.
Patient selection: essential thrombocythemia by WHO criteria
Parameters:
(1) age in years
(2) white blood cell count
(3) history of thrombosis
Parameter |
Finding |
Points |
age in years |
< 60 years of age |
0 |
|
>= 60 years of age |
2 |
WBC count |
< 11,000 per µL |
0 |
|
>= 11,000 per µL |
1 |
history of thrombosis |
no |
0 |
|
yes |
1 |
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the greater the risk of thrombosis and the worse the survival.
Score |
Risk Group |
20 Year Survival |
10 Year Thrombosis Free Survival |
0 |
low |
86% |
89% |
1 or 2 |
intermediate |
64% |
84% |
3 or 4 |
high |
24% |
69% |
Specialty: Hematology Oncology
ICD-10: ,